Chimeric Therapeutics Limited
Chimeric Therapeutics Limited
Your view on CHMMF
Overview
What the company does, where it operates, and who runs it.
About Chimeric Therapeutics Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Rebecca McQualter
- Headquarters
- 62 Lygon Street, Carlton, VIC, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Rebecca McQualter
- Headquarters
- 62 Lygon Street, Carlton, VIC, AU
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies in oncology in Australia.
The company develops CHM 0201 (core NK platform) that is in phase I clinical trial for treating solid tumors and hematological malignancies; and CHM 1101 (CLTX CAR T), which is in phase I clinical trial for treating patients with MMP2+ recurrent or progressive glioblastoma.
It is also developing CHM 0301 for blood cancers; CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK) for solid tumors; CHM 1101 (CLTX CAR T) for melanoma, colorectal, and prostate; and CHM 2101 (CDH17 CAR T) for neuroendocrine, colorectal, pancreatic, and gastric. The company was incorporated in 2020 and is based in Carlton, Australia.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Chimeric Therapeutics Limited, and the rating behind it. CHMMF last traded at $0.0010; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Chimeric Therapeutics Limited. Starting points for Chimeric Therapeutics Limited: EPS -$1.50, beta 1.49 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Chimeric Therapeutics Limited. Chimeric Therapeutics Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Chimeric Therapeutics Limited. Trailing twelve-month EPS for Chimeric Therapeutics Limited stands at -$1.50. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Chimeric Therapeutics Limited. Chimeric Therapeutics Limited has reported as a listed company since 2022. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Chimeric Therapeutics Limited valued side by side against its closest peers. Chimeric Therapeutics Limited is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Chimeric Therapeutics Limited, and how their positions are changing. At a $4.4M market value, institutional positions materially move Chimeric Therapeutics Limited's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Chimeric Therapeutics Limited executives and directors. Shares of Chimeric Therapeutics Limited have traded between $0.0010 and $0.0010 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Chimeric Therapeutics Limited. Chimeric Therapeutics Limited is a $4.4M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Chimeric Therapeutics Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Chimeric Therapeutics Limited. Coverage tracks Chimeric Therapeutics Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.